Quick Answer
Tango Therapeutics, Inc. reported Total Revenue of $62.38 million for fiscal year 2025.
Tango Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $62.38M +48.3% |
$42.07M +15.2% |
$36.53M +46.9% |
$24.86M -32.9% |
$37.04M +383.8% |
$7.66M |
| Net Income | -$101.59M +22.0% |
-$130.30M -28.1% |
-$101.74M +5.9% |
-$108.18M -85.8% |
-$58.23M -12.1% |
-$51.97M |
| Diluted EPS | -$0.87 +26.9% |
-$1.19 -10.2% |
-$1.08 +12.2% |
-$1.23 -30.9% |
-$0.94 | — |
| Total Assets | $398.69M +26.0% |
$316.49M -21.4% |
$402.57M -7.8% |
$436.47M -12.7% |
$500.15M +141.3% |
$207.25M |
| Cash and Equivalents | $112.28M +61.5% |
$69.53M +4.7% |
$66.39M +10.7% |
$59.97M -58.0% |
$142.75M +403.0% |
$28.38M |
| Stockholders Equity | $346.18M +73.5% |
$199.52M -21.2% |
$253.11M +1.5% |
$249.48M -27.6% |
$344.75M +793.1% |
$38.60M +388.3% |
| R&D Expense | $132.16M -8.2% |
$143.92M +24.9% |
$115.20M +8.8% |
$105.91M +36.4% |
$77.64M +55.3% |
$49.99M |
| Operating Income | -$111.29M +23.6% |
-$145.59M -27.5% |
-$114.17M -2.8% |
-$111.07M -90.9% |
-$58.19M -11.5% |
-$52.20M |
| Shares Outstanding | 135.94M +26.2% |
107.73M +5.4% |
102.20M +15.9% |
88.18M +0.8% |
87.47M +116.7% |
40.37M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $53.81M | +363.6% | +1591.6% |
| Net Income | September 30, 2025 | $15.88M | +154.5% | +140.9% |
| Diluted EPS | September 30, 2025 | $0.13 | +148.1% | +137.1% |
| Total Assets | September 30, 2025 | $210.14M | -40.4% | -11.7% |
| Cash and Equivalents | September 30, 2025 | $58.34M | +9.8% | +48.5% |
| Stockholders Equity | September 30, 2025 | $160.03M | -30.2% | +18.6% |
| R&D Expense | September 30, 2025 | $30.82M | -7.4% | -6.1% |
| Operating Income | September 30, 2025 | $14.07M | +142.8% | +134.3% |
| Shares Outstanding | September 30, 2025 | 111.57M | +3.9% | +0.6% |
- Tango Therapeutics, Inc. reported Total Revenue of $62.38 million for fiscal year 2025.
- Tango Therapeutics, Inc. showed an increase of +48.3% in Total Revenue compared to the prior fiscal year.
- Tango Therapeutics, Inc. reported Net Income of -$101.59 million for fiscal year 2025.
- Tango Therapeutics, Inc. showed an increase of +22.0% in Net Income compared to the prior fiscal year.
- Tango Therapeutics, Inc. reported Diluted EPS of $0.87 per share (loss) for fiscal year 2025.
- Tango Therapeutics, Inc. showed an increase of +26.9% in Diluted EPS compared to the prior fiscal year.
- Tango Therapeutics, Inc. reported Total Assets of $398.69 million for fiscal year 2025.
- Tango Therapeutics, Inc. showed an increase of +26.0% in Total Assets compared to the prior fiscal year.
- Tango Therapeutics, Inc. reported Cash and Equivalents of $112.28 million for fiscal year 2025.
- Tango Therapeutics, Inc. showed an increase of +61.5% in Cash and Equivalents compared to the prior fiscal year.
- Tango Therapeutics, Inc. reported Stockholders Equity of $346.18 million for fiscal year 2025.
- Tango Therapeutics, Inc. showed an increase of +73.5% in Stockholders Equity compared to the prior fiscal year.
- Tango Therapeutics, Inc. reported R&D Expense of $132.16 million for fiscal year 2025.
- Tango Therapeutics, Inc. showed a decrease of -8.2% in R&D Expense compared to the prior fiscal year.
- Tango Therapeutics, Inc. reported Operating Income of -$111.29 million for fiscal year 2025.
- Tango Therapeutics, Inc. showed an increase of +23.6% in Operating Income compared to the prior fiscal year.
- Tango Therapeutics, Inc. reported Shares Outstanding of 135.94 million shares for fiscal year 2025.
- Tango Therapeutics, Inc. showed an increase of +26.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: